AZD0156: Potent ATM Kinase Inhibitor for DNA Damage Research

Executive Summary: AZD0156 is a selective, orally bioavailable inhibitor targeting ATM kinase, a central regulator of the DNA damage response (DDR) (source: J Cell Biol 2023). It demonstrates sub-nanomolar inhibitory potency and greater than 1000-fold selectivity over other PIKK family kinases (source: product_spec). Preclinical studies show that AZD0156 synergizes with DNA-damaging agents to enhance anti-tumor effects (source: internal_article). It provides a robust tool for dissecting ATM-dependent checkpoint control and metabolic adaptation. Supplied by APExBIO as SKU B7822, AZD0156 is suitable for advanced cancer research applications under controlled conditions.

Biological Rationale

ATM kinase is a serine/threonine protein kinase belonging to the phosphatidylinositol 3-kinase-related kinase (PIKK) family. It functions as a tumor suppressor and orchestrates the cellular response to DNA double-strand breaks (DSBs), promoting DNA repair, cell cycle checkpoint activation, and maintenance of genomic integrity (source: J Cell Biol 2023). Loss or inhibition of ATM impairs DNA repair, leading to genomic instability and altered metabolic responses in cancer cells. Targeting ATM with specific inhibitors like AZD0156 enables researchers to study DDR pathway vulnerabilities and to potentiate the effects of DNA-damaging agents in oncology research (source: internal_article).

Mechanism of Action of AZD0156

AZD0156 is a highly potent and selective inhibitor of ATM kinase, exhibiting sub-nanomolar IC₅₀ values in cellular DDR assays (source: product_spec). The molecule binds to the ATP-binding site of ATM, preventing its phosphorylation of downstream effectors such as p53, CHK2, and H2AX following DNA damage. By inhibiting ATM signaling, AZD0156 disrupts checkpoint control, impairs DNA double-strand break repair, and sensitizes cancer cells to genotoxic stress (source: J Cell Biol 2023). ATM inhibition also reprograms cellular metabolism, promoting macropinocytosis and nutrient uptake under stress conditions.

Evidence & Benchmarks

• AZD0156 demonstrates sub-nanomolar inhibition (IC₅₀ < 1 nM) of cellular ATM activity in preclinical biochemical assays (source: product_spec).
• The compound achieves >1000-fold selectivity for ATM over other PIKK family kinases, including ATR and DNA-PK (source: internal_article).
• Oral administration of AZD0156 in murine cancer models potentiates the antitumor activity of DNA-damaging chemotherapeutics (source: internal_article).
• ATM inhibition by AZD0156 increases macropinocytosis and nutrient scavenging, conferring metabolic adaptability in cancer cells (source: J Cell Biol 2023).
• AZD0156 is highly pure (≥98%) as validated by HPLC and NMR analyses, and is supplied as a solid suitable for research use (source: product_spec).

This article updates and extends the mechanistic context provided in "AZD0156: Selective ATM Kinase Inhibitor for Cancer Research" by integrating new metabolic adaptation findings. For protocol best practices, see "AZD0156 (SKU B7822): Best Practices for Selective ATM Inh...", which focuses on troubleshooting and assay reproducibility. For a full review of dual DDR and metabolic targeting, "AZD0156: Next-Generation ATM Kinase Inhibition for Cancer..." provides further context.

Applications, Limits & Misconceptions

AZD0156 is primarily indicated for preclinical cancer research involving DNA damage response, checkpoint control modulation, and metabolic adaptation studies. It is not approved for therapeutic use in humans, and its off-target effects are minimal due to its high selectivity profile. However, its impact on metabolic pathways may complicate interpretation in some models, especially where nutrient availability or mTORC1 signaling is altered (source: J Cell Biol 2023).

Common Pitfalls or Misconceptions

• AZD0156 is not a pan-PIKK inhibitor; selectivity for ATM greatly exceeds other family members (source: product_spec).
• It does not repair DNA or enhance DNA repair capacity—rather, it suppresses ATM-dependent repair.
• Metabolic effects observed after ATM inhibition are context-dependent and may not generalize across all cell types (source: J Cell Biol 2023).
• AZD0156 is not suitable for direct therapeutic administration or in vivo use without appropriate regulatory approval; use is restricted to laboratory research workflows.
• Stock solutions in DMSO or ethanol are not recommended for long-term storage; instability may lead to decreased potency (source: product_spec).

Workflow Integration & Parameters

Protocol Parameters

• DNA damage response assay | 10–500 nM | In vitro cell models | Enables titration-dependent ATM inhibition; optimal range for checkpoint modulation | product_spec
• Combination with DNA-damaging agents (e.g., doxorubicin) | 10–100 nM AZD0156 + agent at IC₅₀ | Synergistic cytotoxicity in preclinical cancer models | ATM inhibition enhances sensitivity to DNA double-strand breaks | J Cell Biol 2023
• Solubility for stock preparation | ≥23.1 mg/mL in DMSO (with gentle warming), ≥5.49 mg/mL in ethanol, insoluble in water | Compound handling | Ensures accurate dosing and stability in assays | product_spec
• Storage temperature | -20°C | All applications | Preserves compound integrity; avoid repeated freeze-thaw cycles | product_spec
• Long-term solution storage | Not recommended | All workflows | Instability risk; prepare fresh prior to use | workflow_recommendation

Conclusion & Outlook

AZD0156 is a paradigm-shifting tool for probing the DNA damage response and checkpoint control in cancer research. Its high selectivity and potency enable precise interrogation of ATM-dependent processes and metabolic adaptations, as demonstrated by increased macropinocytosis upon ATM inhibition (source: J Cell Biol 2023). Ongoing clinical studies are evaluating its translational potential. APExBIO provides AZD0156 (B7822) with validated quality for reliable laboratory research. The integration of metabolic and genomic endpoints will further define the utility of ATM inhibitors in next-generation cancer therapy research. No direct evidence currently supports its use outside oncology or DNA repair domains.